What’s going on with the Novacyt (NCYT) share price?

After months of decline, the Novacyt (NCYT) share price started rising last month. Is this a sign to buy? Zaven Boyrazian takes a closer look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a rough almost-half-year for the Novacyt (LSE:NCYT) share price. Despite surging throughout 2020, and the early part of 2021, the stock crashed in April and has continued trending downward. But just last month, it popped back up again and managed to shift the 12-month performance to around +24%.

It’s still nowhere close to where it was at the start of the year. But could the recent jump be an indicator that the firm’s woes are over? And should I be considering this business for my portfolio?

NCYT share price jumps on earnings

Last month, Novacyt published its six-month performance report. And at first glance, it was pretty impressive. The diagnostics specialist brought in £94.7m in revenue. That’s about 50% higher than in 2020, so I can see why the market reacted positively to the news. However, on closer inspection, this trading update may not be as fantastic as it seems.

I’ve previously explored what triggered the NCYT share price to crash in April. But as a quick reminder, the firm’s biggest source of income is a single contract with the Department of Health and Social Care (DHSC). Under this agreement, Novacyt supplies the NHS with Covid-19 testing kits. And it has proven to be a very lucrative deal, which was behind the stock’s surge last year.

Unfortunately, this contract was not extended as originally anticipated. And overnight, the vast majority of the firm’s revenue stream evaporated. Of the £94.7m reported as revenue this year, £40.8m originates from the DHSC and is currently in dispute. In other words, it remains unpaid.

The Novacyt NCYT share price has its risks

It’s not all bad news

A more honest picture of the group’s performance can be seen by its non-DHSC income. This came in at around £53.9m, up around 20% versus last year. That’s still a good level of growth, and it seems it will continue throughout the rest of 2021. Why? Because Novacyt has managed to acquire several new contracts.

Firstly, its subsidiary, Primerdesign, has signed a new deal with the DHSC worth £4.7m, which runs until March 2022. The management team has also negotiated an extension with UNICEF to keep supplying Covid-19 tests until July 2022. Meanwhile, testing in the private sector continues to see high demand for Novacyt products, especially its latest generation of testing kits that can detect the key variants of Covid-19.

Consequently, management has posted a revenue forecast for the year of £100m, excluding income from its disputed DHSC contract. And compared to non-DHSC income last year, this is a notable increase. If the company can continue to grow moving forward, the NCYT share price could recover over the long term.

The bottom line

It’s encouraging to see the group’s revenue stream start to recover the recently-lost income. And, more importantly, diversify its revenue sources. However, one glaring issue I spotted in this latest update is the lack of information surrounding how the business will thrive in a post-pandemic world.

Currently, almost all sales are generated by Covid-related products. But the demand for these will naturally start declining as the pandemic comes to an end. Therefore, until management can answer how it plans to continue growing over the long term, I’ll be keeping this business on my watchlist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »